News
-
-
REGULATED PRESS RELEASE
bioMérieux obtient l’autorisation de la FDA américaine pour la nouvelle version de son test moléculaire ciblant les causes de la gastroentérite, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
bioMérieux reçoit l'autorisation de la FDA américaine pour son test moléculaire BIOFIRE® FILMARRAY® Gastrointestinal Panel Mid ciblant la gastroentérite -
REGULATED PRESS RELEASE
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
bioMérieux receives U.S. FDA clearance for the new version of its molecular test, the BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid, targeting causes of gastroenteritis. The test detects 11 common bacteria, viruses, and parasites from one sample in about 1 hour, improving patient outcomes -
-
-
-
-
-
-
